Peregrine Pharmaceuticals reported $138.81M in Loan Capital for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Loan Capital Change
Acceleron Pharma XLRN:US $ 0M 0M
Agenus AGEN:US $ 18.95M 0.03M
Amgen AMGN:US $ 28458M 2671M
AstraZeneca AZN:LN 24601M 6727M
Biocryst Pharmaceuticals BCRX:US $ 263.66M 9.32M
Bristol Myers Squibb BMY:US $ 42503M 2002M
Celldex Therapeutics CLDX:US $ 0M 0M
Chemocentryx CCXI:US $ 11.57M 3.3M
Dicerna Pharmaceuticals DRNA:US $ 0M 0M
Eli Lilly And LLY:US $ 14736.6M 1463M
Flexion Therapeutics FLXN:US $ 220.02M 14.99M
GlaxoSmithKline GSK:LN 20442M 2605M
Immunogen IMGN:US $ 0M 0M
Karyopharm Therapeutics KPTI:US $ 301.38M 59.58M
Kindred Biosciences KIN:US $ 15.35M 1.58M
Macrogenics MGNX:US $ 0 0
Mannkind MNKD:US $ 280.26M 45.66M
Minerva Neurosciences NERV:US $ 0M 0M
Newlink Genetics NLNK:US $ 0M 0M
Novartis NOVN:VX SF 26491M 908M
Novavax NVAX:US $ 331.94M 7.15M
Peregrine Pharmaceuticals PPHM:US $ 138.81M 41.86M
Xencor XNCR:US $ 0M 0M